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A BS TR AC T
BACKGROUND
Progesterone has been associated with robust positive effects in animal models of 
traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, 
controlled trials. We investigated the efficacy and safety of progesterone in a large, 
prospective, phase 3 randomized clinical trial.
METHODS
We conducted a multinational placebo-controlled trial, in which 1195 patients, 16 to 
70 years of age, with severe TBI (Glasgow Coma Scale score, ≤8 [on a scale of 3 to 15, 
with lower scores indicating a reduced level of consciousness] and at least one reac-
tive pupil) were randomly assigned to receive progesterone or placebo. Dosing be-
gan within 8 hours after injury and continued for 120 hours. The primary efficacy 
end point was the Glasgow Outcome Scale score at 6 months after the injury.
RESULTS
Proportional-odds analysis with covariate adjustment showed no treatment effect of 
progesterone as compared with placebo (odds ratio, 0.96; confidence interval, 0.77 
to 1.18). The proportion of patients with a favorable outcome on the Glasgow 
Outcome Scale (good recovery or moderate disability) was 50.4% with progester-
one, as compared with 50.5% with placebo. Mortality was similar in the two groups. 
No relevant safety differences were noted between progesterone and placebo.
CONCLUSIONS
Primary and secondary efficacy analyses showed no clinical benefit of progesterone 
in patients with severe TBI. These data stand in contrast to the robust preclinical 
data and results of early single-center trials that provided the impetus to initiate 
phase 3 trials. (Funded by BHR Pharma; SYNAPSE ClinicalTrials.gov number, 
NCT01143064.)
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Traumatic brain injury (TBI) is a ma-jor cause of death and disability, with large direct and indirect costs to society. In the 
United States, more than 1.7 million persons have 
a TBI annually,1 and the annual burden of TBI has 
been estimated at more than $76 billion.2 Globally, 
the incidence of TBI is increasing, particularly in 
developing countries.3 Although in recent years 
there has been a heightened interest in mild TBI 
and concussion, the problem of more severe TBI 
remains substantial, despite improvements in trau-
ma systems and critical care. Mortality rates of 
approximately 40% have been reported in a review 
of unselected observational studies.4
TBI is a progressive disorder, in which the pri-
mary injury initiates a complex sequence of bio-
chemical and metabolic changes that lead to 
progressive tissue damage and cell death. These 
secondary events offer opportunities for therapeu-
tic intervention. Multiple pathophysiological mech-
anisms are active in this complex disorder, with 
contusions, diffuse axonal injury, hemorrhage, 
and systemic insults occurring to varying de-
grees.5,6 Potential therapeutic agents may need 
to target multiple mechanisms in order to be 
clinically effective.
Progesterone has been shown to have broad 
neuroprotective properties in multiple animal 
species and in a variety of models of neurologic 
injury. Multifactorial effects of progesterone in-
clude inhibition of inflammatory cytokines, re-
duced levels of inflammation-related factors, pre-
vention of excitotoxicity, reduction of apoptosis, 
and control of vasogenic edema.7-10 The progester-
one receptor plays a key role in these neuroprotec-
tive effects.11 A total of 20 research groups work-
ing with four species and 22 different models have 
found neuroprotective effects of progesterone in 
more than 180 experimental pharmacologic 
studies.12 In addition, two phase 2 randomized, 
controlled clinical trials with progesterone 
showed a clinical benefit.13,14 On the basis of 
these collective data, two phase 3 trials were 
initiated at around the same time: the Study of a 
Neuroprotective Agent, Progesterone, in Severe 
Traumatic Brain Injury (SYNAPSE) and the Pro-
gesterone for the Treatment of Traumatic Brain 
Injury (PROTECT III) trial.15
SYNAPSE, a trial sponsored by BHR Pharma, 
was designed to investigate the clinical effective-
ness of progesterone, provided in a 6% soybean-
oil emulsion as a ready-to-use formulation, under 
well-controlled conditions. The PROTECT III trial, 
funded by the National Institutes of Health, was 
conducted in parallel, but the study was halted on 
the basis of a futility analysis performed after 882 
patients had undergone randomization. Here, we 
report the results of the completed SYNAPSE trial.
ME THODS
STUDY DESIGN
We conducted a multinational, prospective, dou-
ble-blind, parallel-group trial in which patients 
with severe TBI were randomly assigned to intra-
venous progesterone or placebo. Randomization 
was performed from July 2010 through September 
2013. Patients were recruited at level 1 or equiva-
lent trauma centers in 21 countries. The trial pro-
tocol (available with the full text of this article at 
NEJM.org) was approved by regulatory authori-
ties in each country and by the local or regional 
ethics committee for each participating center. 
This report is consistent with the study design 
and procedures presented in the protocol.
ELIGIBILITY
A total of 10,519 male and female patients, 16 to 
70 years of age, with severe nonpenetrating TBI 
were screened for eligibility at admission to the 
study hospitals. Eligibility criteria included a 
Glasgow Coma Scale (GCS) score, assessed after 
resuscitation, of 8 or less (on a scale from 3 to 15, 
with lower scores indicating a reduced level of 
consciousness), a Marshall classification score16 
of II or higher (on a scale from I to VI, with a 
score ≥II indicating visible pathologic changes or 
worse, as assessed on the basis of computed to-
mography [CT]), at least one reactive pupil, a 
body weight of 45 to 135 kg, initiation of treatment 
within 8 hours after injury, and a clinical indica-
tion for monitoring the intracranial pressure.
Patients were excluded if they had a GCS score 
of 3 and bilaterally fixed and dilated pupils, a 
life expectancy of less than 24 hours, prolonged 
or uncorrectable hypoxemia (partial pressure of 
arterial oxygen, <60 mm Hg), hypotension (sys-
tolic blood pressure, <90 mm Hg) at the time of 
randomization, spinal cord injury, pregnancy, only 
an isolated epidural hematoma, or coma that 
was suspected to be due primarily to other 
causes. A complete list of inclusion and exclu-
sion criteria is provided in the Supplementary 
Appendix, available at NEJM.org.
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Because all the potential participants were 
unconscious at the time of study entry, written 
informed consent was obtained from a legally 
acceptable representative before randomization, 
according to national regulations and ethics-com-
mittee requirements. In some countries, consent 
for participation was allowed to be provided by 
an independent physician.
STUDY PROCEDURES AND TREATMENTS
Randomization was implemented with the use of 
an interactive Web-based response system, with a 
block design of four stratified according to geo-
graphic region (Asia, Europe, North America, and 
South America). Patients were randomly assigned 
in a 1:1 ratio to receive progesterone or placebo. 
General treatment and the treatment of raised 
intracranial pressure were in accordance with 
published international guidelines.17
The study drugs (progesterone and placebo) 
were provided in 250-ml bottles with identical 
appearance, containing a lipid emulsion consist-
ing of 6% soybean oil and 1.2% egg lecithin 
phospholipids, with the addition of 2.0 mg of pro-
gesterone per milliliter for the active treatment 
(BHR-100, Fresenius Kabi). Drug infusion was 
started intravenously with a loading dose of 
0.71 mg per kilogram of body weight per hour 
for 1 hour, followed by 0.50 mg per kilogram per 
hour for 119 hours, through a dedicated peripheral 
intravenous catheter or dedicated lumen of a multi-
lumen central catheter.
During the first 6 days, arterial blood gases, 
intracranial pressure, cerebral perfusion pressure, 
and therapeutic intensity levels (a score of all 
therapies used to control elevated intracranial 
pressure) were recorded. Standard laboratory as-
sessments were performed on days 6 and 15, and 
a second CT study was scheduled to be performed 
on day 6. Patients were monitored for “neuro-
worsening,” as defined by Morris et al.,18 daily 
through day 15 (see the study protocol for defini-
tion of neuroworsening). Concurrent medica-
tions, surgeries, and adverse events were record-
ed for the first 15 days, and serious adverse events 
were recorded throughout the duration of the 
study; patients with such events were followed 
until resolution or for at least 6 months. Two 
follow-up visits were planned for 90 (±15) days 
and 180 (±30) days after injury, at which time 
the outcome measures were assessed.
Clinical data were collected through an elec-
tronic data-capture system with built-in data 
checks. All CT scans were reviewed and scored 
by a central reader.
OUTCOME MEASURES
The primary outcome measure was the Glasgow 
Outcome Scale (GOS) score at 6 months after the 
injury. The GOS and the Extended GOS (GOS-E) 
were administered with the use of a structured 
interview by a trained local staff member and 
were scored by the investigator according to the 
standardized approach.19 The GOS captures in-
formation on the degree of recovery in terms of 
disability and handicap due to brain injury rather 
than impairment. The scale has five levels: death, 
vegetative state, severe disability, moderate dis-
ability, and good recovery; death and vegetative 
state were collapsed for the analysis in this study 
because they were considered to be equally unde-
sirable.
Secondary outcome measures included the 
GOS score at 3 months, mortality at 1 month 
and 6 months, and the GOS-E score. The GOS-E 
differs from the GOS in that the three higher 
functional levels (severe disability, moderate dis-
ability, and good recovery) are each subdivided 
into a lower and upper category. Additional sec-
ondary outcome measures included changes in 
intracranial pressure, cerebral perfusion pressure, 
and therapeutic intensity levels, along with chang-
es in intracranial pathologic findings as assessed 
on the CT scan obtained on day 6. The 36-Item 
Short-Form Health Survey (SF-36) scale was ad-
ministered at 3 and 6 months to assess quality of 
life for those patients able to complete the scale.
STUDY OVERSIGHT
An independent data and safety monitoring board 
periodically reviewed blinded data. Staff from PRA 
Health Sciences and INC Research conducted on-
site visits to assess protocol compliance and ad-
herence to Good Clinical Practice guidelines and 
to perform data verification and query resolution. 
Medical monitors reviewed selected data central-
ly, and representatives of the sponsor regularly 
visited the study sites to monitor study compli-
ance. The steering committee (see the Supplemen-
tary Appendix) assisted the sponsor with study 
design, data interpretation, and the development 
of the manuscript. Data management and statis-
tical analysis was performed by PRA Health Sci-
ences. Analyzable datasets were provided to the 
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steering committee for a check of analyses and 
further exploratory analyses. The decision to sub-
mit the manuscript for publication was made by 
the steering committee and was approved by the 
sponsor. The members of the steering committee 
vouch for the integrity of the data and analyses.
STATISTICAL ANALYSIS
We estimated that a sample of 1180 patients, with 
a 1:1 randomization ratio, would be required for 
the study to detect an odds ratio of 1.50, indicat-
ing an improvement in outcome (10% effect size) 
at the 1% significance level (two-sided). The sam-
ple-size estimation was based on the use of a pro-
portional-odds model20 to analyze the primary out-
come variable (GOS score at 6 months after injury).
The analyses were performed on data from the 
modified intention-to-treat population, which ex-
cluded 16 patients who never received the study 
drug. This approach was agreed to by the Food 
and Drug Administration. In the proportional-
odds analysis, covariate adjustment was performed 
for geographic region (Asia, Europe, North Amer-
ica, and South America) and the baseline values 
of age, GCS motor score (score of 1 or 2 vs. 3 vs. 
4 vs. 5 or 6, on a scale from 1 to 6, with lower 
scores indicating a lower level of consciousness), 
pupillary response (bilateral response vs. unilat-
eral response, no reactive pupils, or not testable), 
and Marshall classification (I or II vs. III vs. IV 
vs. V or VI). 
As a secondary evaluation, efficacy was ana-
lyzed with the use of a sliding dichotomy21 of the 
GOS outcome at 6 months. Baseline prognostic 
risk was calculated by means of the model devel-
oped by Hukkelhoven et al.,22 and patients were 
then ranked according to prognostic risk and 
categorized into three groups on the basis of the 
prognosis (worst, intermediate, and best). The slid-
ing dichotomy provides a means to assess each 
of the three prognostic groups individually in-
stead of the entire group, increasing the sensitiv-
ity of the analysis. The analysis used a Cochran–
Mantel–Haenszel chi-square test with adjustment 
for geographic region.
R ESULT S
STUDY PARTICIPANTS AND DRUG LEVELS
Patients were recruited from July 2010 through 
September 2013, with the final 6-month visit oc-
curring by the end of March 2014. A total of 1195 
patients underwent randomization, with intrave-
nous administration of progesterone initiated in 
591 patients and placebo administered in 588 pa-
tients (the modified intention-to-treat population); 
16 patients were excluded because they did not 
receive the assigned study drug. Of the 1179 pa-
tients in the modified intention-to-treat popula-
tion, 96.0% were followed for 6 months or died 
before 6 months (Fig. 1). There were no meaning-
ful protocol violations. After centralized assess-
ment of CT scans, less than 1% of the patients 
who had undergone randomization were in Mar-
shall classification I (i.e., no radiologically sig-
nificant abnormality on baseline CT).
Baseline characteristics, including GCS over-
all score and motor score, Marshall classification, 
and pupillary reactivity, were similar in the two 
groups (Table 1). Drug-level assessment was per-
formed 2 days after the initial dosing. Progester-
one treatment resulted in a median progesterone 
level of 333.5 ng per milliliter (interquartile range, 
268.9 to 405.7; 1061 nmol per liter [interquartile 
range, 855 to 1290]); this value was similar to the 
mean level obtained in the phase 2 PROTECT 
trial (347 ng per milliliter [1103 nmol per liter]), 
which provided the early support for the current 
trial. Drug levels in the cerebrospinal fluid were 
not monitored.
CLINICAL OUTCOMES
The primary end point, the GOS score at 6 months, 
did not differ significantly between the progester-
one group and the placebo group (Table 2). The 
proportional-odds model revealed no effect of 
progesterone treatment in either unadjusted or ad-
justed analyses (adjusted odds ratio, 0.96; 95% 
confidence interval [CI], 0.77 to 1.18). The propor-
tion of patients with an overall favorable outcome 
(good recovery or moderate disability) on the GOS 
was 50.4% in the progesterone group and 50.5% 
in the placebo group. The proportion of patients 
who were in a vegetative state or who died was 
also similar in the two groups: 22.2% in the pro-
gesterone group and 22.3% in the placebo group 
(Table S1 in the Supplementary Appendix). The 
GOS-E also did not reveal significant differences 
between the two study groups at 3 or 6 months.
SECONDARY OUTCOMES
The sliding dichotomy, which relates outcome to 
baseline prognostic risk, revealed no significant 
differences between progesterone treatment and 
The New England Journal of Medicine 
Downloaded from nejm.org at TAMPERE UNIVERSITY LIBRARY on February 16, 2016. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Progesterone for Severe Tr aumatic Br ain Injury
n engl j med 371;26 nejm.org december 25, 2014 2471
placebo (Fig. 2). This approach showed no indi-
cation of efficacy in the groups based on prog-
nosis (worst, intermediate, and best) (Table S2 in 
the Supplementary Appendix shows results of 
analyses of baseline prognostic factors). The 
subgroup analyses according to Marshall clas-
sification, decompressive craniectomy (yes vs. 
no), any other surgery (yes vs. no), and isolated 
head injury versus multiple trauma showed no 
significant odds ratios (Table 2). Cerebral per-
fusion pressure and therapeutic intensity levels 
did not differ significantly between the proges-
terone group and the placebo group (Tables S3 
and S4 in the Supplementary Appendix). Data on 
the SF-36, which were available for a total of 723 
patients at 6 months (74.2% of survivors), re-
vealed no significant differences in physical or 
mental composite summary scores.
ADVERSE EVENTS
The distribution of adverse events is shown in 
Table 3. There were no significant differences in 
the rate of adverse events between progesterone 
treatment and placebo.
1195 Underwent randomization
9324 Were excluded
8345 Did not meet eligibility criteria
130 Had LAR who declined consent
541 Did not have LAR available
308 Had other reasons
597 Were assigned to receive progesterone
591 Received progesterone
6 Did not receive progesterone
(eligibility reevaluated, patient died, 
or administrative reason)
598 Were assigned to receive placebo
588 Received placebo
10 Did not receive placebo (eligibility
reevaluated, patient died, consent
withdrawn, or administrative reason)
14 Were lost to follow-up after treatment
95 Died (included in analysis)
4 Discontinued intervention owing to
withdrawn consent
4 Discontinued intervention owing to
investigator decision
1 Had adverse event
17 Were lost to follow-up after treatment
109 Died (included in analysis)
7 Discontinued intervention owing to
withdrawn consent
591 Were included in modified intention-
to-treat analysis
25 included with imputed 6-mo GOS score
588 Were included in modified intention-
to-treat analysis
24 included with imputed 6-mo GOS score
10,519 Patients were assessed for eligibility
Figure 1. Study Enrollment, Randomization, and Follow-up of the Patients.
The modified intention-to-treat population excluded 16 patients (6 patients in the progesterone group and 10 in the 
placebo group) because they did not receive any study drug. A total of 31 patients (17 patients in the progesterone 
group and 14 in the placebo group) were lost to follow-up. A total of 204 patients (109 patients in the progesterone 
group and 95 in the placebo group) died before 6 months of follow-up. Data on 1179 patients were included in the 
efficacy analysis. Missing values were first imputed by carrying forward the Glasgow Outcome Scale (GOS) assess-
ment at month 3. If a participant did not have a GOS score at 3 or 6 months, the missing value was imputed with 
the use of the proportional-odds model. LAR denotes legally acceptable representative.
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DISCUSSION
Our results do not support the hypothesized su-
periority of progesterone treatment over placebo 
in patients with severe TBI, as assessed by means 
of the GOS or mortality. TBI is a complex, het-
erogeneous disorder, in which the primary injury 
initiates a variety of secondary injury cascades. 
These cascades involve various processes that may 
not be responsive to monotherapy, as has been 
shown by the failure of previously studied mono-
therapies that have targeted single receptors or 
specific mechanisms,23,24 despite considerable sup-
portive experimental data. Systemic and extra-
neuronal effects of trauma also require consider-
ation with respect to their effect on mortality 
Table 1. Baseline Characteristics of the Modified Intention-to-Treat Population.*
Characteristic
Progesterone
(N = 591)
Placebo
(N = 588)
Age — yr
Median 35 34
Interquartile range 23–51 24–50
Male sex — no. (%) 464 (78.5) 463 (78.7)
Geographic region†
Asia 62 (10.5) 58 (9.9)
Europe 279 (47.2) 277 (47.1)
North America 219 (37.1) 220 (37.4)
South America 31 (5.2) 33 (5.6)
Cause of injury — no. (%)
Motor vehicle or motorcycle accident 369 (62.4) 364 (61.9)
Fall 124 (21.0) 142 (24.1)
Sports or recreation accident or other event 98 (16.6) 82 (13.9)
Glasgow Coma Scale score — no. (%)‡
Overall score
3 52 (8.8) 64 (10.9)
4–6 262 (44.3) 276 (46.9)
7 or 8 276 (46.7) 248 (42.2)
Data missing 1 (0.2) 0
Motor score
1–3 213 (36.0) 241 (41.0)
4–6 376 (63.6) 345 (58.7)
Data missing 2 (0.3) 2 (0.3)
Pupillary response — no. (%)
Both reacting 480 (81.2) 475 (80.8)
One reacting 109 (18.4) 107 (18.2)
Other or untestable 2 (0.3) 6 (1.0)
Marshall classification — no. (%)§
I 6 (1.0) 4 (0.7)
II 235 (39.8) 233 (39.6)
III or IV 213 (36.0) 199 (33.8)
V or VI 134 (22.7) 151 (25.7)
Data missing 3 (0.5) 1 (0.2)
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among patients with TBI.25 These complex injury 
mechanisms suggest that a successful therapeu-
tic agent should influence several mechanisms 
rather than a single cascade.
On the basis of the experimental data, proges-
terone would appear to be an appropriate candi-
date for this pluripotential role, having been 
shown to prevent inflammation by inhibiting 
the production of inflammatory cytokines (e.g., 
tumor necrosis factor α), as well as by reducing 
levels of inflammation-related factors such as 
complement factor C3 fragments and inhibiting 
the activation of microglial cells. In addition, 
progesterone has been shown to prevent excito-
toxicity and limit apoptosis by preventing bio-
chemical insults, such as calcium (Ca2+) flux and 
nitric oxide production, and by decreasing levels 
of caspase 3. Finally, progesterone has also been 
shown to limit vasogenic edema through recon-
stitution of the blood–brain barrier and modula-
tion of the aquaporin-4 water transporter.26
Preliminary clinical data obtained with the 
use of various progesterone formulations and 
routes of delivery, combined with experimental 
data showing adequate brain penetration, pro-
vided initial support for a neuroprotective role of 
progesterone in TBI. The initial PROTECT trial13 
recruited 100 patients from a single site who had 
a GCS score of 4 to 12. Treatment was initiated 
within 11 hours after injury, with a 72-hour 
treatment duration, and was associated with a 
reduction in the rate of death from any cause, as 
compared with placebo (13.0% vs. 30.4%; rela-
tive risk, 0.43; 95% CI, 0.18 to 0.99). A similar 
single-site trial14 in China recruited 159 patients 
who had a GCS score of 8 or lower. Progesterone 
treatment, which was initiated within 8 hours 
after injury by means of intramuscular injection, 
with a 120-hour treatment duration, was associ-
ated with reduced mortality, as compared with 
placebo (18% vs. 32%, P = 0.04). The time win-
dows and duration of treatment in SYNAPSE 
were based largely on these two studies.
The long history of failed TBI trials, including 
the current trial, is probably due to several fac-
tors, including the complexity and variability of 
the injury and the fact that multiple direct and 
indirect injury mechanisms are at work simulta-
neously. There may also be insensitivity of the 
available outcome measures. The lack of mecha-
nistic early end points and the absence of reli-
able biomarkers to guide clinical development 
and inform clinical-trial design may be consid-
ered to be major obstacles to the development of 
neuroprotective agents for TBI. In addition, cur-
rent approaches to the characterization of TBI 
are mainly unidimensional (based on GCS scores 
or Marshall classification) and do not permit 
Table 1. (Continued.)
Characteristic
Progesterone
(N = 591)
Placebo
(N = 588)
Traumatic subarachnoid hemorrhage — no. (%)¶ 449 (76.0) 456 (77.6)
Confirmed or suspected hypoxemia — no. (%)‖ 52 (8.8) 45 (7.7)
Confirmed or suspected hypotension — no. (%)**  93 (15.7)  78 (13.3)
Time from injury to first dose
Median 7 hr 4 min 7 hr 2 min
Interquartile range 6 hr 0 min to 7 hr 45 min 5 hr 53 min to 7 hr 45 min
* There were no significant between-group differences at baseline.
† Geographic regions were defined as follows: Asia included China, Malaysia, Singapore, Taiwan, and Thailand; Europe 
included Austria, Belgium, the Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, the Netherlands, and 
Romania; North America included the United States; and South America included Argentina.
‡ Overall scores on the Glasgow Coma Scale range from 3 to 15, with lower scores indicating a reduced level of con-
sciousness. Motor scores range from 1 to 6, with lower scores indicating a reduced motor response.
§ The Marshall classification is based on a review of CT scans, with a score of I indicating normal findings, II indicating 
diffuse injury, III or IV indicating radiologic signs of elevated intracranial pressure, and V or VI indicating a mass lesion.
¶ Data were missing for 4 patients in the progesterone group and for 1 in the placebo group.
‖ Hypoxemia was defined as a partial pressure of arterial oxygen of less than 60 mm Hg. Data were missing for 16 pa-
tients in the progesterone group and for 22 in the placebo group.
** Hypotension as defined as a systolic blood pressure of less than 90 mm Hg. Data were missing for 14 patients in the 
progesterone group and for 12 in the placebo group.
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appropriately targeted therapy. Multidimension-
al approaches are needed for better characteriza-
tion of TBI in order to facilitate individualized 
treatment.27
Limitations in the ability to translate experi-
mental data to the context of TBI in humans 
may also have contributed to the trial failures. A 
more systematic approach appears to be neces-
sary to advance therapeutics in TBI. The basic 
science consortium approach currently under way, 
as a part of the Combat Casualty Care Research 
Program entitled Operation Brain Trauma Ther-
apy Consortium, may be one improvement in drug-
candidate selection.28
In conclusion, our data indicate that proges-
terone, as administered in this trial, had no clinical 
benefit in the treatment of severe TBI. The negative 
result of this study, combined with the results of 
Table 2. Results of Efficacy Analysis in the Modified Intention-to-Treat Population.*
Outcome
Progesterone
(N = 591)
Placebo
(N = 588)
Odds Ratio
(95% CI)
Primary efficacy analysis — no. (%)† 0.96 (0.77–1.18)
Dead or vegetative state 131 (22.2) 131 (22.3)
Severe disability 162 (27.4) 160 (27.2)
Moderate disability 109 (18.4) 114 (19.4)
Good recovery 189 (32.0) 183 (31.1)
Subgroup analyses — no.‡
Geographic region
Asia 61 56 1.35 (0.65–2.80)
Europe 267 265 0.81 (0.58–1.14)
North America 208 210 1.36 (0.93–2.00)
South America 30 32 0.46 (0.17–1.27)
Marshall classification
I or II 221 222 1.01 (0.69–1.49)
III or IV 205 192 0.95 (0.64–1.41)
V or VI 130 145 0.94 (0.58–1.53)
Decompressive craniectomy
Yes 132 97 0.86 (0.50–1.48)
No 434 466 1.10 (0.84–1.42)
Surgery
Yes 401 377 0.93 (0.70–1.23)
No 175 186 1.11 (0.73–1.69)
Injury
Head injury alone 77 65 0.81 (0.42–1.57)
Multiple trauma 489 498 1.04 (0.81–1.33)
Time to first dose
≤6 hr 144 157 1.31 (0.83–2.07)
>6 hr 422 406 0.92 (0.70–1.21)
* CI denotes confidence interval.
† The primary analysis was performed as a proportional-odds analysis with adjustment for the following baseline vari-
ables: geographic region, age, Glasgow Coma Scale motor score, pupillary response, and Marshall classification. The 
unadjusted analysis yielded similar results (odds ratio, 0.98; 95% CI: 0.79 to 1.21).
‡ Subgroup analyses were restricted to patients with complete outcome data at 6 months, and treatment effects were an-
alyzed according to the dichotomized Glasgow Outcome Scale (favorable vs. unfavorable). An odds ratio of more than 
1.00 represents a benefit of active treatment; the results of the unadjusted analysis are presented.
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Table 3. Adverse Events in the Safety Population, According to Organ Class and Preferred Term.*
Event Progesterone (N = 596) Placebo (N = 583)
no. of patients (%) no. of events no. of patients (%) no. of events
Any event 582 (97.7) 4025 570 (97.8) 4018
Blood or lymphatic system disorder 194 (32.6) 259 211 (36.2) 282
Cardiac disorder 133 (22.3) 159 129 (22.1) 157
Endocrine disorder 44 (7.4) 45 52 (8.9) 54
Gastrointestinal disorder 184 (30.9) 235 186 (31.9) 254
Infection or infestation 389 (65.3) 599 400 (68.6) 604
Pneumonia 208 (34.9) 221 222 (38.1) 239
Sepsis 46 (7.7) 48 40 (6.9) 40
Urinary tract infection 28 (4.7) 30 36 (6.2) 36
Nervous system disorder 266 (44.6) 450 246 (42.2) 389
Brain edema 32 (5.4) 34 28 (4.8) 30
Intracranial pressure increased 130 (21.8) 196 137 (23.5) 163
* The safety population included all participants who underwent randomization and received at least one dose of the 
study drug. The specific adverse events listed are those that occurred during treatment in more than 5% of all the study 
patients.
P=0.36 P=0.82 P=0.38
Outcome
Worst Prognosis
(N=393)
Intermediate Prognosis
(N=394)
Best Prognosis
(N=392)
Death
Vegetative state
Severe disability
Moderate disability
Good recovery
Unfavorable
64 (34.6%)
Favorable
121 (65.4%)
Favorable
127 (61.1%) Favorable
96 (46.6%)
Favorable
85 (45.2%) Favorable
97 (48.5%)
Favorable
102 (53.1%)
Unfavorable
81 (38.9%) Unfavorable
110 (53.4%)
Unfavorable
103 (54.8%) Unfavorable
103 (51.5%)
Unfavorable
90 (46.9%)
Progesterone
(N=185)
Placebo
(N=208)
Progesterone
(N=206)
Placebo
(N=188)
Progesterone
(N=200)
Placebo
(N=192)
Figure 2. Efficacy Analysis with the Use of a Sliding Dichotomy Approach.
In the sliding dichotomy approach, the GOS was dichotomized for analysis, but the split for dichotomy was differ-
entiated according to the baseline prognostic risk. Prognostic groups (based on worst, intermediate, and best prog-
nosis)22 were defined by baseline prognostic factors that included age, Glasgow Coma Scale motor score (1 or 2 vs. 
3 vs. 4 vs. 5 or 6; scores range from 1 to 6, with lower scores indicating reduced motor response), pupillary re-
sponse (bilateral response vs. unilateral response, no reactive pupils, or not testable), presence or absence of hy-
poxemia, presence or absence of hypotension, Marshall’s classification (I or II vs. III vs. IV vs. V or VI), and pres-
ence or absence of traumatic subarachnoid hemorrhage. The Marshall classification is based on a review of CT 
scans; scores range from I to VI, with a score of II or higher indicating visible pathologic changes or worse. The 
arrow indicates the split for sliding dichotomy differentiated according to prognostic risk. P values were based on a 
Cochran–Mantel–Haenszel chi-square test with adjustment for geographic region (Asia, Europe, North America, 
and South America).
The New England Journal of Medicine 
Downloaded from nejm.org at TAMPERE UNIVERSITY LIBRARY on February 16, 2016. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;26 nejm.org december 25, 20142476
Progesterone for Severe Tr aumatic Br ain Injury
the PROTECT III trial,15 should stimulate a re-
thinking of procedures for drug development and 
testing in TBI.
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